187 related articles for article (PubMed ID: 15577320)
1. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
[TBL] [Abstract][Full Text] [Related]
2. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Muhonen T; Turunen JP; Hahka-Kemppinen M; Pyrhönen S
J Clin Oncol; 1996 May; 14(5):1690-6. PubMed ID: 8622089
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Turunen JP; Muhonen T; Pyrhönen S
J Immunother; 1997 Nov; 20(6):488-95. PubMed ID: 9409455
[TBL] [Abstract][Full Text] [Related]
4. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
5. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma.
Muhonen T; Hahka-Kemppinen M; Pakkala S; Pyrhönen S
J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):67-73. PubMed ID: 7509188
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
7. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
9. DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma.
Hahka-Kemppinen M; Muhonen T; Nordling S; Pyrhönen S
Melanoma Res; 1997 Aug; 7(4):329-34. PubMed ID: 9293483
[TBL] [Abstract][Full Text] [Related]
10. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
Hernberg M; Muhonen T; Pyrhönen S
Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.
Verdegaal EM; Visser M; Ramwadhdoebé TH; van der Minne CE; van Steijn JA; Kapiteijn E; Haanen JB; van der Burg SH; Nortier JW; Osanto S
Cancer Immunol Immunother; 2011 Jul; 60(7):953-63. PubMed ID: 21431917
[TBL] [Abstract][Full Text] [Related]
13. Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
Vuoristo MS
Melanoma Res; 1996 Aug; 6(4):331-6. PubMed ID: 8873054
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
Konjević G; Jović V; Radomirović V; Spuzić I
Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
[TBL] [Abstract][Full Text] [Related]
15. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
Mulder NH; van der Graaf WT; Willemse PH; Koops HS; de Vries EG; Sleijfer DT
Br J Cancer; 1994 Oct; 70(4):681-3. PubMed ID: 7522510
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy.
Hansen BD; Schmidt H; von der Maase H; Sjoegren P; Agger R; Hokland M
Acta Oncol; 2006; 45(4):400-5. PubMed ID: 16760175
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Kivelä T; Suciu S; Hansson J; Kruit WH; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
Eur J Cancer; 2003 May; 39(8):1115-20. PubMed ID: 12736111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
